by Dr. Ed Weber | Nov 30, 2021 | PCa Commentary
mHSPC: Genomic basis for choice of therapy for men diagnosed with metastatic cancer prior to initial treatment. Decisions regarding therapy for men with mHSPC will become an increasingly relevant issue as the use of the 68Ga-PSMA-PET/CT and the newly approved...
by Dr. Ed Weber | Oct 23, 2021 | PCa Commentary
The previous PCa Commentary (Vol. 157) pca-commentary-157-metastatic-hormone-sensitive-prostate cancer/ [control+click link to follow or visit https://prostatecancerfree.org/prostate-cancer-news] addressed the evolution of systemic therapy regimens in de-novo mHSPC...
by Dr. Ed Weber | Sep 29, 2021 | PCa Commentary
Metastatic Hormone Sensitive Prostate Cancer refers to cancers which are found to have metastasized at diagnosis prior to primary treatment and therefore have not been exposed to testosterone deprivation. The incidence of this stage of cancer at diagnosis increased...
by Dr. Ed Weber | Aug 25, 2021 | PCa Commentary
“Pylarify” is a recently FDA approved tracer for imaging the prostate specific membrane antigen (PSMA) displayed on ~95% of prostate cancer cells. This urea-based radiotracer combines the small molecule DCFPyL, a PSMA targeting agent, with the positron-emitting...
by Dr. Ed Weber | Jul 27, 2021 | PCa Commentary, Uncategorized
Hot flashes are an especially unpleasant adverse effect of androgen deprivation therapy (ADT). They occur with varying intensity in about 70% of men undergoing treatment. Hot flashes (also termed hot flushes) are experienced as a feeling of increased of body heat...
